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Abstract
Loss-of-function mutations in SCN1A cause Dravet syndrome (DS), a catastrophic childhood epilepsy in which
patients experience comorbid behavioral conditions, including movement disorders, sleep abnormalities, anxiety, and
intellectual disability. To study the functional consequences of voltage-gated sodium channel mutations, we use
zebrafish with a loss-of-functionmutation in scn1lab, a zebrafish homolog of human SCN1A. Homozygous scn1labs552/s552
mutants exhibit early-life seizures, metabolic deficits, and early death. Here, we developed in vivo assays using
scn1labs552 mutants between 3 and 6 d postfertilization (dpf). To evaluate sleep disturbances, we monitored
larvae for 24 h with locomotion tracking software. Locomotor activity during dark (night phase) was significantly
higher in mutants than in controls. Among anticonvulsant drugs, clemizole and diazepam, but not trazodone or
valproic acid, decreased distance moved at night for scn1labs552 mutant larvae. To monitor exploratory behavior
in an open field, we tracked larvae in a novel arena. Mutant larvae exhibited impaired exploratory behavior, with
increased time spent near the edge of the arena and decreased mobility, suggesting greater anxiety. Both
clemizole and diazepam, but not trazodone or valproic acid, decreased distance moved and increased time spent
in the center of the arena. Counting inhibitory neurons in vivo revealed no differences between scn1labs552
mutants and siblings. Taken together, our results demonstrate conserved features of sleep, anxiety, and
movement disorders in scn1lab mutant zebrafish, and provide evidence that a zebrafish model allows effective
tests of treatments for behavioral comorbidities associated with DS.
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Introduction
Voltage-gated sodium channels are responsible for
generation and propagation of neuronal action potentials
in central and peripheral nervous systems. Mutations of
these channels are a major cause of genetically inherited
epilepsies and other neurologic disorders (Dichgans
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Significance Statement
Certain mutations cause severe genetic diseases that affect brain development, leading to seizures, cognitive
impairment, and abnormal behaviors in affected children. One of the best studied of these genetic diseases is
Dravet syndrome (DS), which results from mutations in a channel that normally controls sodium flux in the brain.
Although the genetic cause of DS is known, no effective treatment is available. Animals, including zebrafish,
share sodium channels that are similar to the human ones, and mutating a sodium channel also leads to an
epilepsy disorder in developing zebrafish. We found that zebrafish with a DS-like mutation also exhibit problems
with locomotion, sleep, and anxiety, and that these behaviors were modulated by antiepileptic drugs.
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et al., 2005; Meisler and Kearney, 2005; Catterall, 2014;
Waxman et al., 2014). SCN1A, which encodes the pore-
forming alpha subunit of Nav1.1, is expressed throughout
mammalian nervous systems, primarily in axon initial seg-
ments and nodes of Ranvier (Gordon et al., 1987; Duflocq
et al., 2008). Confirming the conserved importance of
Nav1.1 for neural function, homologs of SCN1A are pres-
ent in other vertebrates, including teleost fishes (Novak
et al., 2006a,b; Widmark et al., 2011).
Nonsense and missense mutations in SCN1A are as-
sociated with a catastrophic epilepsy of childhood known
as Dravet syndrome (DS; Escayg et al., 2000; Claes et al.,
2001; Sugawara et al., 2002; Harkin et al., 2007; Depienne
et al., 2009; Dravet, 2011; Catterall, 2014). In DS, seizures
commonly appear in the first year of life (often accompa-
nied by fever), and progress to prolonged myoclonic,
atypical absence, or focal events with frequent status
epilepticus episodes requiring emergency care (Gataullina
and Dulac, 2017). Generalized and multifocal abnormali-
ties are seen in the electroencephalography. Starting as
early as the second year of life, DS children develop
comorbid conditions such as psychomotor regression,
motor disorder, abnormal sleep microarchitecture, and
intellectual disability (Nolan et al., 2006; Martin et al.,
2010; Dhamija et al., 2014). The risk for premature death
is also high in this patient population (Genton et al., 2011).
Unfortunately, effective treatments are not available to
address the range of seizure phenotypes and comorbidities
associated with DS (Chiron and Dulac, 2011; Catterall, 2014;
Wilmshurst et al., 2014). Studies in animal models, which
now include zebrafish as well as mice, offer a means to
address this problem (Catterall, 2014; Grone and Baraban,
2015; Kaplan et al., 2016).
Mice with heterozygous deletion of Scn1a reproduce
many DS phenotypes, including epilepsy with early onset
(Yu et al., 2006; Ogiwara et al., 2007), susceptibility to
febrile seizures (Oakley et al., 2009), sleep and circadian
abnormalities (Han et al., 2012a; Papale et al., 2013), and
premature death (Kalume et al., 2013). Reduced neuronal
excitability and behavioral abnormalities are also found in
Scn1a mutant mice (Han et al., 2012b; Ito et al., 2013).
Although mice offer strengths for understanding the basic
biology and physiology of ion channels and for testing
treatments, they are not ideally suited to drug discovery.
Zebrafish have emerged as a powerful model organism
for analyzing genetic diseases (Ablain and Zon, 2013; De-
ciphering Developmental Disorders Study, 2015; Grone
et al., 2016; Tuschl et al., 2016). Zebrafish with a missense
loss-of-function mutation in scn1lab, one of two SCN1A-
like genes found in teleost fishes (Novak et al., 2006b),
show oculomotor defects, early life seizures, pharmaco-
resistance, and metabolic deficits (Schoonheim et al.,
2010; Baraban et al., 2013; Kumar et al., 2016; Sourbron
et al., 2016). Like Scn1a null mice, which develop ataxia
and die at about postnatal day 15 (Yu et al., 2006; Ogi-
wara et al., 2007), homozygous scn1labs552/s552 mutant
larvae do not survive beyond 14 d postfertilization (dpf;
Schoonheim et al., 2010). This well-conserved overall
phenotype suggests that the scn1lab gene in zebrafish
shares essential conserved functions with mammalian
Scn1a. Whether scn1lab mutant zebrafish exhibit comor-
bidities normally associated with DS, including movement
disorders, anxiety, or sleep disturbances, is not known.
Here, we provide the first assessments of these behaviors
in a zebrafish model of DS, i.e., scn1labs552 mutants. We
used a set of assays based on zebrafish sleep patterns
(Zhdanova et al., 2001; Yokogawa et al., 2007; Rihel et al.,
2010), and behavioral responses to novel environments
(Richendrfer et al., 2012; Schnörr et al., 2012; Ahmad and
Richardson, 2013). We found that the homozygous
scn1labs552 mutants exhibit nighttime hyperactivity, de-
creased time spent in the center of an open arena, and
decreased responsiveness to sudden darkness. Diazepam
and clemizole have previously been found to suppress con-
vulsive seizure behaviors in this model (Baraban et al., 2013;
Griffin et al., 2017). We found that both of these drugs also
reduced nighttime locomotor activity and the time spent in
the center of the open field. Taken together, our results
suggest that behavioral comorbidities can be studied in
larval zebrafish models of genetic epilepsies, and that these
mutant fish could aid in identifying new treatments.
Materials and Methods
Zebrafish maintenance
Adult male and female zebrafish were maintained ac-
cording to standard procedures (Westerfield, 2000) and
following guidelines approved for this study by the University
of California, San Francisco Institutional Animal Care and
Use Committee. The Tg(1.4dlx5a-dlx6a:GFP) fish line has
been previously described (Ghanem et al., 2003) and was
generously provided by the laboratory of Dr. Marc Ekker.
The scn1labs552 line has been previously described
(Schoonheim et al., 2010) and was generously provided
by the laboratory of Dr. Herwig Baier. Zebrafish of the TL
strain were obtained from the Zebrafish International Re-
source Center (ZIRC). The zebrafish room was maintained
on a 14/10 h light/dark cycle, with lights-on at 9 A.M. and
lights-off at 11 P.M. Fish system water conditions were
maintained in the following ranges by automated feed-
back controls: 29–30°C, pH 7.5–8.0, conductivity (EC)
690–710. Zebrafish embryos and larvae were raised in an
incubator maintained at 28.5°C, on the same light-dark
cycle as the fish facility. At 5 dpf, zebrafish have not yet
experienced sexual differentiation (Liew and Orbán,
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2014). Water used for embryos and larvae (“embryo me-
dium”) was made by adding 0.03% Instant Ocean and
0.000002% methylene blue to reverse-osmosis distilled
water. Embryos and larvae were raised in plastic Petri
dishes (90 mm in diameter, 20 mm in depth) and their
housing density was limited to 60 individuals per dish.
Pharmacology
The following drugs were dissolved in dimethylsulf-
oxide (DMSO, Sigma-Aldrich) to 10 mM as stock solutions,
and stored at 20°C until needed: caffeine (Sigma),
clemizole-HCl (Tocris), diazepam (Sigma-Aldrich), trazod-
one-HCl (Sigma-Aldrich), and valproic acid sodium salt
(Sigma-Aldrich).
Behavioral phenotyping, diurnal activity
To monitor diurnal activity patterns, scn1labs552/s552 lar-
vae were placed individually in wells of a flat-bottom
96-well Falcon culture dish (BD Biosciences) and move-
ment was tracked continuously during a 24-h period,
which included 14 h light-on and 10 h light-off phases.
Each well contained 200 l of embryo medium. Behav-
ior was monitored at room temperature (21–22°C) using
two DanioVision systems and EthoVision XT locomotion
tracking software version (Noldus). The older system with
EthoVision XT 8 software was used for initial experiments
(Fig. 1). The newer system with EthoVision XT 11 software
was used for all other experiments. Total distance moved
measurements were consistent within systems, but not
comparable between systems as the software detection
parameters and image quality are not identical on the two
systems; 5-dpf larvae were allowed to acclimate to the
tracking arena for 3–4 h, and then 24 h of continuous
behavioral data were recorded beginning at 4 P.M. The
light-dark cycle continued as usual: lights-off occurred at
11 P.M. and lights-on at 9 A.M.
Behavioral phenotyping, open field
Open field behavior was examined in wells of a six-well
plate, each containing 6 ml of egg water; 5-dpf zebrafish
larvae were placed individually in separate wells, using a
glass Pasteur pipette. Larvae are initially placed near the
center of the arena, but tend to shift slightly as the plate is
transferred into the recording apparatus. Using EthoVi-
sion, 5 min of tracking data were immediately recorded
with no acclimation period. The video data were analyzed
in 30-s time bins. For each group, we calculated distance
traveled and time spent in the center zone (diameter 
25.5 mm) of the well (inner diameter  36.6 mm).
For drug treatment trials, drugs in DMSO were diluted in
embryo medium to a final concentration of 250 M, 25
M, or 2.5 M, as described (with 2.5% DMSO). Ze-
brafish larvae were incubated in embryo medium contain-
ing the drug or DMSO for 30 min before transfer to the
open field (in groups of three fish in 2 ml of solution in a
well of a 24-well plate). Individual larvae were then trans-
ferred to a single well of a six-well plate containing DMSO
(2.5%) or drug dissolved in DMSO, for the duration of the
assay.
Cell count
For imaging of interneurons, we in-crossed scn1labs552/;
Tg(1.4dlx5a-dlx6a:GFP) adult zebrafish. Green fluorescent
protein (GFP)-expressing larvae were raised in PTU and
imaged at 5 dpf using a Zeiss Z.1 light sheet microscope
with 20 objective. The sample chamber was filled with
embryo medium. Zebrafish larvae were anesthetized in
0.04% tricaine mesylate for 10 min, then embedded in 2%
Figure 1.Mutant scn1labs552 larvae had statistically significantly more locomotor activity at night compared to wild-type (WT) siblings.
Larval zebrafish (5 dpf) were placed in individual wells of a flat-bottom 96-well plate and acclimated to the recording chamber.
Twenty-four hours of movement data were collected beginning at 4 P.M. A, Data shown are sums of 10-min bins  SD (N  12 WT,
31 Mut). The dark bar at the bottom indicates the 10-h period when lights were turned off, 11 P.M. to 9 A.M. B, Total nighttime
distance moved by WT and homozygous mutant (s552/s552) larvae. Boxplot shows median, quartiles, and whiskers extending to the
furthest point within 1.5 IQR (dot plots are shown, with outliers excluded). p  0.05.
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low melting point agarose inside a glass capillary. Image
stacks were taken extending from the first dorsal GFP-
positive neuron, at intervals of 4.94 m with 20 slices per
fish. Imaging files were coded and analyzed post hoc by
an investigator blind to phenotype and genotype. Follow-
ing imaging, the fish were removed from agar and geno-
typed.
FIJI software was used for analysis of image stacks
(Schindelin et al., 2012). Cells were counted automatically
using 3D Objects Counter.
Genotyping
For genotyping, we extracted genomic DNA (gDNA)
from whole larvae using the Zebrafish Quick Genotyping
DNA Preparation kit (Bioland Scientific). We amplified
scn1lab gDNA using GoTaq Green Master Mix (Promega)
and the following primers: scn1lab-F, AAATCTCTCTGT-
TAGACAGAAATTGGGG and scn1lab-R, TTGCTCAG-
GCTGTGTGATGAGG. These primers amplify a 314-bp
region, including the scn1lab mutation site. The mutant
allele was then detected by digestion of the amplicon with
AcuI, for which a restriction site is introduced in the
mutant, and electrophoresis to separate the digested
samples on a 1% agarose gel.
Statistics and graphing
JASP version 0.8.0.1 software was used for statistical
tests (https://jasp-stats.org/). Microsoft Excel, R software
(R Core Team, 2016) and the beeswarm package were
used for plotting data.
Results
Diurnal locomotor activity is altered in mutant larvae
To assess diurnal movements indicative of sleep/wake
cycles, we tracked larvae from scn1labs552/ in-crosses
continuously during a 24-h light/dark period (Zhdanova
et al., 2001; Yokogawa et al., 2007; Rihel et al., 2010;
Elbaz et al., 2013). To quantify disruptions to sleep activ-
ity, total distance moved during the dark (sleep) period
was compared between groups. Distance moved at night
(11 P.M. to 9 A.M.) showed statistically significant differ-
ences between genotypes: scn1labs552/s552 traveled a
greater distance compared to wild-type siblings (Fig. 1B).
Welch’s t test showed a difference between genotypes
(mean  SEM, measured in mm): wild type, 5622.7 
1181.5 (N  12); homozygous 10,084.0  1244.8 (N 
31); t(39.87)  4.410, p  0.001. These differences in
diurnal activity patterns suggest that scn1labs552/s552 lar-
vae exhibit sleep and diurnal rhythm disturbances.
In the final hour before lights-off (10–11 P.M.),
scn1labs552/s552 mutant larvae traveled a greater distance
(2900  327.5) compared to wild-type siblings (1490 
339.3; t(31.14)  2.989; p  0.005). We observed trends
toward increased activity by the mutants in the first hour
of tracking (4-5 P.M.; mutant, 1264  227.8; wild type,
2090  600.3; t(14.29)  1.289, p  0.218), and the first
hour after lights-on (9–10 A.M.; mutant, 2341  162.0;
wild type, 3715  800.5; t(11.91)  1.683, p  0.118), but
these did not reach statistical significance.
Sleep pharmacology
To determine if the observed disruptions of diurnal
rhythms could be pharmacologically alleviated, drug trials
were conducted on scn1labs552/s552 larvae during a full
24-h period. We found that drug treatments could signif-
icantly decrease nighttime locomotor patterns indicative
of wakefulness. We tested two drug concentrations based
on previous reports (Herrmann, 1993; Zhdanova et al.,
2001; Richendrfer et al., 2012; Baraban et al., 2013; Ko-
seki et al., 2014) and pilot experiments; a “low” concen-
tration of 2.5 M and a “high” concentration of 25 M for
four compounds: valproic acid, diazepam, trazodone, and
clemizole (Fig. 2).
At 2.5 M concentration (Fig. 2B), t tests showed no
difference between DMSO and valproic acid, trazodone,
diazepam, or clemizole (Table 1). At 25 M concentration
(Fig. 2D), t tests showed no difference between DMSO
and valproic acid or trazodone. On the other hand, t tests
revealed that two drug treatments led to less distance
traveled compared to DMSO: diazepam and clemizole
(Table 1).
Open field deficits in mutant larvae
To study anxiety-like and locomotor behavior in more
detail, we adapted a version of the open field test (Walsh
and Cummins, 1976). This assay is designed to give tem-
poral as well as spatial resolution regarding position and
movement over time after larvae are introduced to a novel
cylindrical chamber. Single larvae were placed in individual
wells of a flat-bottom six-well plate and movement was
tracked during a 5-min recording epoch. DMSO (2.5%)
was tested for effects on larval behavior compared to
embryo medium using Welch’s t test (N  6 per group).
No significant effects were found for total duration in center
(mean  SEM): water, 87.9  44.7; DMSO, 116.6  45.2
(t(10.0)  0.451, p  0.662) or total distance moved (mean 
SEM, measured in mm): water, 869.8  69.8; DMSO,
815.2 36.0 (t(7.49)  0.695, p  0.508), or any of the
individual time bins.
Representative tracking plots for six larvae per geno-
type are shown in Figure 3. In this assay, scn1labs552/s552
mutant larvae have significantly impaired (low) distance
moved compared to wild-type control sibling larvae. Total
distance moved (Fig. 3B) was different between geno-
types (mean SEM, measured in mm): wild type, 5622.7
1181.5 (N 33); homozygous, 10,084.0 1244.8 (N 18)
by Welch’s t test (t(48.43)  7.256, p  0.001). For time
spent in the center zone (25.5 mm) of the arena (36.6 mm),
homozygous scn1labs552/s552 mutants were significantly
reduced compared to wild-type siblings. Duration in cen-
ter (Fig. 3C) was also different between wild-type and
homozygous mutants (mean  SEM): wild type, 158.2 
11.6 (N  33); homozygous, 81.7  18.1 (N  18) by
Welch’s t test (t(31.11)  3.552, p  0.001).
Open field pharmacology
Next, we pretreated scn1labs552/s552 larvae with drugs
and assessed effects using the open field assay. All drugs
(valproic acid, diazepam, trazodone, and clemizole) were
tested at two different concentrations, 25 M and 250
M. The 25 M concentration of each drug had no sig-
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nificant effect on either time spent in the center or total
movement (Fig. 4). No effect was observed after treatment
of zebrafish larvae with 25 M valproic acid, diazepam,
trazodone, or clemizole on distance moved or duration
spent in the center of the arena in an open field test (N 
18 per group). All drug treatments were compared to
DMSO vehicle using Welch’s t test (Table 2).
On the other hand, the 250 M concentration of either
diazepam or clemizole, the same two drugs with signifi-
cant effects in our sleep assay (Fig. 2), significantly re-
duced the overall locomotor activity we observed while
increasing the duration spent in the center of the arena, a
measure of low-anxiety exploratory behavior (Fig. 4). All
drug treatments were compared to DMSO vehicle using
Welch’s t test. Valproic acid and trazodone had no signifi-
cant effect on distance moved or duration in center (Fig.
4A-D). Diazepam and clemizole decreased distance moved
and increased duration in center (Fig. 4E-H).
The effects of clemizole and diazepam, which signifi-
cantly modified open field behavior in scn1labs552/s552
larvae, were also tested further in wild-type larvae of the
TL strain (Fig. 5). Clemizole and diazepam were compared
to DMSO in the same experiment (N  18 per group).
For total distance traveled during the 5-min assay,
clemizole (153.3  17.84) and diazepam (10.25  2.76),
led to significant reductions compared to the control
DMSO-treated larvae (529.0 88.26), using Welch’s t test
(clemizole: t(18.39)  4.172, p  0.001; diazepam: t(17.03) 
5.875, p  0.001). In TL larvae, we found no significant
effects of either clemizole (117.0  20.45) or diazepam
(136.1 35.4) on total duration in center measured in mm,
compared to DMSO (89.1  19.1), using Welch’s t test
Figure 2. Full 24-h light-dark cycle behavioral data reveal effects of treatment with 2.5 M (A, B) and 25 M (C, D) concentrations
of drugs in DMSO. Both diazepam and clemizole, at 25 M concentration, significantly decreased distance moved at night compared
to vehicle (DMSO)-treated control. Mean values (N  8 individuals per group) per 10-min time bin are shown at left (A, C). Total
night-time distances moved (during 10 h of darkness), are shown at right (B, D). Boxplot shows median, quartiles, and whiskers
extending to the furthest point within 1.5 IQR (dot plots are shown, with outliers excluded). The 2.5 M concentration of each drug
had no significant effect on total nighttime locomotor activity, an indicator of wakefulness (B). On the other hand, the 25 M treatment
with either diazepam or clemizole significantly reduced the nighttime locomotor activity (D). p  0.001.
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(clemizole: t(33.9)  0.999, p  0.325; diazepam: t(26.2) 
1.169, p  0.253).
To further characterize the effects of pharmacological
interventions in our open field assay, we tested the effect
of caffeine at a concentration of 250 M (Maximino et al.,
2011), using the same protocol as applied for the other
drugs. Caffeine-treated wild-type larvae moved signifi-
cantly less (mean  SEM, measured in mm; 333.4 
56.23) than DMSO-treated controls (562.5 105.0; t(32)
2.103, p  0.043), but did not significantly differ in dura-
tion spent in the center of the arena (t(32)  0.679, p 
0.465). In the mutant larvae, we observed no significant
effects of caffeine on either total distance traveled (t(37) 
1.428, p  0.162) or duration spent in the center of the
arena (t(37)  0.425, p  0.673).
Interneuron density
Because mutations in mammalian Scn1a, which is ex-
pressed in inhibitory interneurons, impair interneuron fir-
ing activity (Yu et al., 2006; Mistry et al., 2014), we
examined interneuron numbers at 5 dpf. To visualize in-
terneurons scn1labs552/s552 were crossed with a zebrafish
line expressing a transgene with GFP flanked by both a
3.5-kb fragment of the dlx6 promoter and a 1.4-kb fragment
of the dlx5/6 intergenic region (Ghanem et al., 2003). This
reporter line labels distinct populations of interneurons
(Robles et al., 2011). To evaluate interneuron density we
conducted live light-sheet microscopy of scn1labs552/s552;
Tg(1.4dlx5a-dlx6a:GFP) larvae (Fig. 6). Live imaging revealed
cells labeled by GFP in the telencephalon, optic tectum,
cerebellum, and diencephalon. In an imaging stack centered
on the optic tectum, we counted GFP-positive cells for
scn1labs552/s552 and sibling larvae. Welch’s t test was used
to test for differences between genotypes (mean  SEM):
wild type, 144.9  11.7 (N  8); homozygous, 135.7  17.5
(N  12). No statistically significant effect of genotype was
found (t(17.99)  0.406, p  0.690).
Discussion
Behavioral deficits greatly decrease quality of life for DS
patients. Our findings here demonstrate that zebrafish
provide useful models of behavioral as well as neurophys-
iological symptoms of epileptic encephalopathies such as
DS. While Scn1a haploinsufficiency is known to cause
sleep and circadian abnormalities, hyperactivity, autistic-
and anxiety-like behavior in mouse models, these comor-
bidities have not been previously investigated in a sys-
tematic way in scn1lab mutant zebrafish. The significant
behavioral differences from wild-type larvae, as demon-
strated here, and their sensitivity to pharmacological
treatments, expand the repertoire of assays that can be
used to characterize zebrafish models for neurologic dis-
ease and uncover new treatments.
Sleep
Evidence from patients, mice, and zebrafish suggest
that SCN1A homologs play a conserved role in regulating
motor activity and daily patterns of locomotion. Zebrafish,
including larvae, are diurnal in laboratory conditions, with
a light-entrainable circadian clock (Cahill et al., 1998).
Wild-type larvae exhibit hallmarks of sleep, including im-
mobility, increased arousal threshold that can rapidly be
reversed, characteristic posture, and sleep rebound fol-
lowing deprivation (Zhdanova et al., 2001). Sleep in ze-
brafish can be quantified as bouts of immobility at night
(Elbaz et al., 2013). Our assay simplifies this approach to
measure activity levels in day and night without specifying
the microstructure of rest bouts. We found disrupted
levels of locomotor activity at several points throughout
the light-dark cycle, with a consistently increased activity
in scn1labs552/s552 larvae compared to wild types during
the dark phase. Like humans, and in contrast to mice,
zebrafish sleep at night, making them a useful model for
diurnal behavioral patterns. High levels of cycling alter-
nating pattern activity in non-REM sleep were reported in
DS patients (Dhamija et al., 2014). Scn1a/mice similarly
exhibit disrupted circadian activity patterns compared to
controls, with decreased activity in the active (dark) phase
and increased activity in the rest (light) phase (Han et al.,
2012a). Mice with a heterozygous knockin missense Scn1a
mutation showed increased wakefulness in the active
(dark) phase (Papale et al., 2013). Taken together, data
from zebrafish and mouse models suggest that diurnal
behavioral deficits associated with mutations in SCN1A
homologs may be an important and conserved feature of
SCN1A deficiency.
Table 1. Night phase movement statistical data
Drug Mean  SEM Student’s t df p Levene’s p Shapiro-Wilk p
(2.5 M)
DMSO control 25,868.7  2606.4 0.308
Valproic acid 24,120.2  3697.7 0.386 14 0.705 0.432 0.651
Trazodone 25,239  1494.6 0.209 14 0.837 0.109 0.068
Diazepam 19,108.0  6247.0 0.999 14 0.335 0.133 0.034
Clemizole 27,076.0  2289.8 0.348 14 0.733 0.594 0.863
(25 M)
DMSO control (30,921.1  4311.6) 0.293
Valproic acid 23,435.8  3465.6 1.353 14 0.197 0.324 0.75
Trazodone 31,490.0  4857.9 0.088 14 0.931 0.932 0.188
Diazepam 6908.1  1916.6 5.089 14 0.001 0.01 0.567
Clemizole 7475.7  3384.2 4.278 14 0.001 0.171 0.001
Larval zebrafish (N  18 per group) were video recorded during the 10-h night phase and total distance was measured for larva treated with DMSO or with
one of four drugs at two concentrations (see Materials and Methods). For DMSO and each drug tested, the table shows distance moved in mm (mean 
SEM), t value, degrees of freedom, and p value (see Results). Data from lower concentration tested (2.5 M) is shown at top; 25 M is shown below.
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Figure 3. Disruptions in open field test behaviors were found in scn1labs552/s552 larvae. Representative traces of movement are shown
(A). Mutant scn1labs552/s552 larvae initially have normal levels of overall movement (B) but spend less time than controls in the center
of the arena (C). At subsequent time points, scn1labs552/s552 larvae’s movement decreases (B) and their time spent in the center of
the arena increases (C). Time bins are 30 s, bars show SEM. On the right, dot plots are shown with boxplot indicating median,
quartiles, and whiskers extending to the furthest point within 1.5 IQR; statistical analyses were conducted on these totals.
p  0.001.
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The increased movement that we observed in
scn1labs552/s552 larvae during the dark phase (night) may
correspond directly to the greater electrical signals that
were detected during the dark phase using a recently
developed microfluidic multielectrode recording chamber
method (Hong et al., 2016). Further development and char-
acterization of zebrafish models of epileptic encephalopa-
thies could reveal important mechanistic insights related to
sleep. Future in vivo imaging and electrophysiologymay also
contribute to our understanding of neural activity patterns
during the course of waking and sleeping (Wang et al., 2011).
Open field exploration
Our open field assay featured high temporal resolution
and revealed severe deficits in open field exploration and
movement. Exploration in an open field assay was simi-
larly disrupted in a zebrafishmecp2mutant model for Rett
syndrome (Pietri et al., 2013). Key features of our assay
include the use of six-well plates with 36.6-mm diameter
wells, pretreatment with drug for 30 min followed by
continuous drug exposure, and immediate recording of
locomotion following addition of the larvae to the novel
wells. Binning the data into 30-s time bins revealed pre-
Figure 4. Treatment with antiepileptic drugs at 250 M. Statistically significant decreases in locomotion (distance traveled) and
duration in the center of the open field were observed after treatment of zebrafish larvae with 250 M diazepam (C, D) or clemizole
(G,H), but not after treatment with valproic acid (A, B) or trazodone (E, F; N 18 per group). Data are plotted in 30-s time bins showing
mean  SEM (left), and the 5-min total for each all individuals, are plotted on the right. p  0.001.
New Research 8 of 13
July/August 2017, 4(4) e0066-17.2017 eNeuro.org
viously unappreciated features of the scn1labs552/s552 mu-
tant larvae behavior that could have been obscured with
larger time bins, including a worsening (decreasing) trend
in distance moved over the 5-min assay, accompanied by
an improving (increasing) amount of time spent in the
center of the arena. In contrast, no evidence was found for
habituation in wild-type larvae in a larger (9.6 cm) dish
over 15 min (using 5-min time bins; Ahmad and Richard-
son, 2013). Reduced overall level of movement appears to
be the primary effect of clemizole and diazepam in wild-
type and mutant larvae, leading to increased variability
and differences in duration spent in the center of the
Table 2. Open field test statistical data
Drug Measurement Treated DMSO control Welch’s t df p
(25 M)
VPA Distance (mm) 287.6  37.31 234.2  29.23 1.127 32.16 0.268
Center duration (s) 91.93  16.54 64.51  17.93 1.124 33.78 0.269
Trazodone Distance (mm) 199.9  29.26 198.0  17.79 0.055 28.05 0.956
Center duration (s) 72.81  21.17 85.73  19.31 0.451 33.72 0.655
Diazepam Distance (mm) 138.5  28.87 175.6  26.73 0.941 33.8 0.354
Center duration (s) 73.25  18.55 66.49  18.03 0.261 33.97 0.796
Clemizole Distance (mm) 177.9  32.12 107.5  15.12 1.983 24.18 0.059
Center duration (s) 49.17  18.93 97.65  22.17 1.663 33.19 0.106
(250 M)
VPA Distance (mm) 293.6  52.82 172.2  26.99 2.047 25.31 0.051
Center duration (s) 91.07  20.05 78.36  18.31 0.468 33.72 0.643
Trazodone Distance (mm) 168.8  38.14 260.1  43.95 1.57 33.34 0.126
Center duration (s) 128.82  21.62 93.96  21.30 1.149 33.99 0.259
Diazepam Distance (mm) 2.56  2.04 73.06  11.40 6.089 18.08 0.001
Center duration (s) 282.07  16.59 59.73  20.15 8.518 32.8 0.001
Clemizole Distance (mm) 36.89  9.61 158.38  32.62 3.572 19.93 0.002
Center duration (s) 83.29  17.31 28.31  6.61 2.967 21.85 0.007
Larval zebrafish (N  18 per group) were pretreated one of four drugs at two concentrations (see Materials and Methods). Each treatment group was tested
at the same time as a control group treated with DMSO. Drug-treated and control larvae were then placed in a novel arena and behavior was video recorded
for 5 min. Both distance moved (mm) and duration spent in center of the arena (s) were measured for all larva. Table shows distance moved in mm (mean 
SEM), t value, degrees of freedom, and p value. Data from lower concentration tested (25 M) is shown at top; 250 M is shown below.
Figure 5. Wild-type TL zebrafish larvae open field behavior is modulated by clemizole and diazepam. Statistically significant
decreases in distance traveled (A) in open field test were observed after treatment of zebrafish larvae with 250 M clemizole or
diazepam, compared to DMSO-treated controls. No statistically significant effects on duration spent in the center (B) were found for
either clemizole or diazepam. p  0.001.
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arena. Our findings correspond directly to the efficacy of
these drugs at this concentration in reducing behavioral
measures of seizures, as shown in previous papers. The
zebrafish open field test, like themouse equivalent, has clear
limitations as an assay of cognitive function, and should be
interpreted with caution as a measure of anxiety since many
factors can influence open field behavior (Walsh and Cum-
mins, 1976). Several other cognitive assays have been re-
ported for adult zebrafish (Meshalkina et al., 2017) but are
not reliably established for larvae. Overall, our results sug-
gest that modifications to the open field assay were impor-
tant for revealing behavioral deficits and could be applied to
a variety of larval zebrafish mutant models.
Pharmacology
Valproic acid, diazepam, trazodone, and clemizole have
all been studied for antiepileptic activity in scn1lab ze-
brafish larvae (Baraban et al., 2013; Griffin et al., 2017).
For these drugs, effects in wild-type zebrafish on diurnal
rhythms (Rihel et al., 2010) or other aspects of locomotion
(Herrmann, 1993; Richendrfer et al., 2012; Baraban et al.,
2013) have also been investigated. Valproic acid, a broad
spectrum antiepileptic drug (Tomson et al., 2016) com-
monly used in DS (Chiron and Dulac, 2011), exerts pro-
tective effects in larval or adult zebrafish exposed to the
chemoconvulsant pentylenetetrazole: (1) decreasing be-
havioral or electrographic seizure activity and (2) improv-
ing deficits in learning of a passive avoidance response
(Lee et al., 2010). Valproic acid has also been shown to
increase “waking” activity in wild-type larvae, with a low-
est effective dose of 15 M (Rihel et al., 2010). Although
valproic acid at a concentration of 1 mM exerted antiepi-
leptic activity in scn1labs552/s552 mutant larvae (Baraban
et al., 2013), no significant effect on behavior was ob-
served here with valproic acid at a concentration of
250 M. Trazodone, a drug commonly prescribed for
insomnia and depression (Rickels et al., 1993; Mendelson,
2005), potentiates the high-speed movements caused by
light flash in larval zebrafish (Koseki et al., 2014), and can
increase rest (Rihel et al., 2010), but had no significant
effects on the behaviors we assayed in the range of
concentrations we tested (2.5-250 M). Diazepam, a ben-
zodiazepine and antiepileptic drug, decreases locomotor
activity, seizures, and measures of anxiety in wild-type ze-
brafish larvae (Zhdanova et al., 2001; Baraban et al., 2005;
Schnörr et al., 2012). Diazepam has been tested at a range
of concentrations from 10 nM up to 1 mM in larval zebrafish
(Zhdanova et al., 2001; Baraban et al., 2005; Richendrfer
et al., 2012; Baraban et al., 2013; Griffin et al., 2017). We
found that 250 M diazepam significantly decreased loco-
motion in an open field test of the scn1labs552/s552 mutant
larvae, extending previous results that showed nearly com-
plete elimination of movements at a 100 M concentration,
compared to minimal effects at a 1 M concentration (Zh-
danova et al., 2001; Baraban et al., 2005). An even higher
concentration of clemizole (667 M) led to nearly complete
elimination of movement in scn1labs552/s552 mutants follow-
ing a brief exposure (Baraban et al., 2013). Clemizole, a
first-generation antihistamine recently identified as a poten-
tial antiepileptic drug acting on serotonin receptors in
scn1labs552/s552 mutant larvae (Baraban et al., 2013; Griffin
et al., 2017), decreased behavioral activity in the hyperactive
scn1labs552/s552 larvae in both the diurnal and open field
assays. Clemizole had no significant effects on locomotion
at concentrations between 6.25 M and 50 M (Baraban
et al., 2013). Similarly, clemizole can also increase “rest”
activity in wild-type larvae (Rihel et al., 2010), supporting our
finding of decreased nighttime locomotion in mutant larvae.
Caffeine, an adenosine receptor antagonist, is thought
to produce anxiogenic effects in fish, rodents, and hu-
mans. Larval zebrafish exposed to caffeine at 100 mg/l
(515 M) exhibited decreased locomotor activity and re-
duced swim speed in the open field test (Maximino et al.,
2011; Richendrfer et al., 2012). A locomotor depressive
effect of high concentrations of caffeine has also been
observed in rodents (Finn and Holtzman, 1986; Svenning-
sson et al., 1995). Our control studies using 250 M
caffeine are consistent with these reports that high con-
centrations of caffeine will decrease locomotor activity in
wild-type larval zebrafish and support a conclusion that
features of exploration and anxiety may be conserved
between larval zebrafish and mammals.
Interneuron density
Interneuron defects are thought to be responsible for
pathology in DS patients (Yu et al., 2006; Ogiwara et al.,
2007; Mistry et al., 2014). Deficits in GABA-mediated
Figure 6. No significant effects of scn1lab mutation were found in
numbers of Tg(1.4dlx5a-dlx6a:GFP) neurons. Neurons were
counted by light-sheet microscopy in 5-dpf larvae, followed by 3D
image segmentation and quantification of discrete objects. Sample
images are shown illustrating GFP fluorescence detected in optic
tectum (A) and telencephalon (B). Representative images (C) are
shown for wild-type and scn1labs552/s552 mutants. Quantification of
cell numbers is shown in (D) as dot plots with boxplot indicating
median, quartiles, and whiskers extending to the furthest point
within 1.5 IQR. No significant effect of genotype was detected.
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inhibition may reflect changes in the number of inhibitory
synapses or neurons. Using in vivo light sheet microscopy
and an interneuron reporter line (i.e., dlx5/6:GFP) we
found no difference in the number of GFP-positive neu-
rons in scn1labs552/s552 mutant larvae and control siblings.
As these GFP cells are primarily GABAergic interneurons
(Robles et al., 2011), our data suggest that interneurons
are present in normal abundance at these early stages of
development. Consistent with our findings in a zebrafish
model, differences in interneuron density in mouse mod-
els of Scn1a deficiency, or patients with DS, have not
been reported.
Conclusion
Some of the greatest advantages of in vivo disease
modeling using larval zebrafish are the ease of genetic
modifications (Varshney et al., 2013; Gagnon et al., 2014;
Li et al., 2016), the broad range of behavioral assays
available (Brockerhoff et al., 1995; Budick and O’Malley,
2000; Fero et al., 2011), and the scalability for phenotype-
based drug screening (Rihel et al., 2010; Gut et al., 2013;
Dinday and Baraban, 2015; Bruni et al., 2016). As dem-
onstrated here, clinically relevant comorbidities such as
sleep, movement disorders, and anxiety can be efficiently
assayed in a larval zebrafish model of DS, despite con-
cerns that “lower model organisms” such as zebrafish
would not allow assessment of comorbid symptoms
(EpiPM Consortium, 2015). Moreover, these assays com-
bined with the unique attributes of larval zebrafish for
higher throughput drug screening (e.g., large clutch sizes,
multi-well readouts, and small-molecule permeation), can
be used for the rapid identification of drugs that reduce
behavioral deficits.
Note Added in Proof: The commercial interest was
accidentally left off the title page of the Early Release
version published August 3, 2017. The commercial inter-
est has now been included in the “Disclosures” section.
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